$LGND Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in LIGAND PHARMACEUTICALS INC. Get notifications about new insider transactions in LIGAND PHARMACEUTICALS INC for free.
Page: < prev 1 ... 6 7 8 9 10 11 12 13 14 ... 15 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 01 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Buy | J | 1.24 | 1,692 | 2,100 | 440,968 | 439.3 K to 441 K (+0.39 %) |
Jul 01 2010 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | J | 1.24 | 7,500 | 9,308 | 100,177 | 92.7 K to 100.2 K (+8.09 %) |
Jun 02 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Buy | P | 1.48 | 5,000 | 7,400 | 86,574 | 81.6 K to 86.6 K (+6.13 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 30,000 | |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 30,000 | |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Grant | A | 0.00 | 5,000 | 0 | 20,000 | 15 K to 20 K (+33.33 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Grant | A | 0.00 | 20,979 | 0 | 66,357 | 45.4 K to 66.4 K (+46.23 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Grant | A | 0.00 | 5,000 | 0 | 45,378 | 40.4 K to 45.4 K (+12.38 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 20,979 | 0 | 81,574 | 60.6 K to 81.6 K (+34.62 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 5,000 | 0 | 60,595 | 55.6 K to 60.6 K (+8.99 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | A | 1.43 | 15,000 | 21,450 | 15,000 | |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Grant | A | 0.00 | 20,979 | 0 | 40,979 | 20 K to 41 K (+104.90 %) |
May 27 2010 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Grant | A | 0.00 | 5,000 | 0 | 20,000 | 15 K to 20 K (+33.33 %) |
May 26 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Buy | P | 1.43 | 7,500 | 10,750 | 55,595 | 48.1 K to 55.6 K (+15.59 %) |
May 26 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Buy | P | 1.45 | 2,803 | 4,064 | 48,095 | 45.3 K to 48.1 K (+6.19 %) |
May 24 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Buy | P | 1.48 | 592 | 874 | 45,292 | 44.7 K to 45.3 K (+1.32 %) |
May 11 2010 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Buy | P | 1.63 | 6,250 | 10,188 | 102,250 | 96 K to 102.3 K (+6.51 %) |
May 11 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Buy | P | 1.67 | 3,200 | 5,344 | 40,378 | 37.2 K to 40.4 K (+8.61 %) |
May 11 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Buy | P | 1.68 | 6,800 | 11,424 | 37,178 | 30.4 K to 37.2 K (+22.38 %) |
Apr 20 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Option Exercise | A | 2.98 | 15,000 | 44,700 | 15,000 | |
Apr 20 2010 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 5,000 | 0 | 44,700 | 39.7 K to 44.7 K (+12.59 %) |
Mar 17 2010 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Sell | J | 1.89 | 7,334 | 13,861 | 74,376 | 81.7 K to 74.4 K (-8.98 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.82 | 2,000 | 3,648 | 62,296 | 64.3 K to 62.3 K (-3.11 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 300 | 512 | 64,296 | 64.6 K to 64.3 K (-0.46 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.82 | 4,600 | 8,390 | 187,990 | 192.6 K to 188 K (-2.39 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.82 | 73,400 | 133,874 | 2,357,528 | 2.4 M to 2.4 M (-3.02 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 20,800 | 35,472 | 2,430,928 | 2.5 M to 2.4 M (-0.85 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.82 | 10,000 | 18,239 | 321,800 | 331.8 K to 321.8 K (-3.01 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 2,900 | 4,946 | 331,800 | 334.7 K to 331.8 K (-0.87 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.82 | 52,600 | 95,937 | 1,046,230 | 1.1 M to 1 M (-4.79 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 13,900 | 23,705 | 1,098,830 | 1.1 M to 1.1 M (-1.25 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.82 | 157,400 | 287,082 | 3,131,883 | 3.3 M to 3.1 M (-4.79 %) |
Mar 16 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 42,100 | 71,797 | 3,289,283 | 3.3 M to 3.3 M (-1.26 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.68 | 16,100 | 26,988 | 2,451,728 | 2.5 M to 2.5 M (-0.65 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 33,100 | 56,601 | 2,467,828 | 2.5 M to 2.5 M (-1.32 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.68 | 1,900 | 3,185 | 334,700 | 336.6 K to 334.7 K (-0.56 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 5,900 | 10,089 | 336,600 | 342.5 K to 336.6 K (-1.72 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.68 | 9,100 | 15,254 | 1,112,730 | 1.1 M to 1.1 M (-0.81 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 23,801 | 40,700 | 1,121,830 | 1.1 M to 1.1 M (-2.08 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.68 | 32,900 | 55,150 | 3,331,383 | 3.4 M to 3.3 M (-0.98 %) |
Mar 12 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 67,200 | 114,912 | 3,364,283 | 3.4 M to 3.4 M (-1.96 %) |
Mar 11 2010 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Option Exercise | A | 2.98 | 15,000 | 44,700 | 15,000 | |
Mar 11 2010 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
Mar 11 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Option Exercise | A | 2.98 | 15,000 | 44,700 | 15,000 | |
Mar 11 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 8,200 | 14,049 | 64,596 | 72.8 K to 64.6 K (-11.26 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.72 | 51,535 | 88,743 | 72,796 | 124.3 K to 72.8 K (-41.45 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 40,800 | 69,903 | 342,500 | 383.3 K to 342.5 K (-10.64 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 12,000 | 20,560 | 1,145,631 | 1.2 M to 1.1 M (-1.04 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.72 | 320,900 | 552,590 | 383,300 | 704.2 K to 383.3 K (-45.57 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.72 | 42,810 | 73,719 | 1,157,631 | 1.2 M to 1.2 M (-3.57 %) |
Mar 10 2010 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 1.71 | 14,000 | 23,986 | 3,431,483 | 3.4 M to 3.4 M (-0.41 %) |
Feb 19 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | A | 2.98 | 15,000 | 44,700 | 15,000 | |
Feb 19 2010 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Grant | A | 0.00 | 5,000 | 0 | 30,378 | 25.4 K to 30.4 K (+19.70 %) |
Feb 19 2010 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | A | 2.98 | 15,000 | 44,700 | 15,000 | |
Feb 19 2010 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
Feb 19 2010 | LGND | LIGAND PHARMACEUTI ... | Burakoff Steven J | Director | Option Exercise | A | 2.98 | 15,000 | 44,700 | 15,000 | |
Feb 19 2010 | LGND | LIGAND PHARMACEUTI ... | Burakoff Steven J | Director | Grant | A | 0.00 | 5,000 | 0 | 15,000 | 10 K to 15 K (+50.00 %) |
Feb 18 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Buy | P | 1.67 | 6,000 | 10,020 | 439,276 | 433.3 K to 439.3 K (+1.38 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Option Exercise | A | 1.66 | 100,000 | 166,000 | 100,000 | |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Grant | A | 0.00 | 18,000 | 0 | 81,710 | 63.7 K to 81.7 K (+28.25 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Grant | A | 0.00 | 6,000 | 0 | 65,710 | 59.7 K to 65.7 K (+10.05 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 1.66 | 100,000 | 166,000 | 100,000 | |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 18,000 | 0 | 92,677 | 74.7 K to 92.7 K (+24.10 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 6,000 | 0 | 61,263 | 55.3 K to 61.3 K (+10.86 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | A | 1.66 | 100,000 | 166,000 | 100,000 | |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Grant | A | 0.00 | 18,000 | 0 | 82,000 | 64 K to 82 K (+28.13 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Grant | A | 0.00 | 6,000 | 0 | 64,000 | 58 K to 64 K (+10.34 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Option Exercise | A | 1.66 | 106,000 | 175,960 | 106,000 | |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Grant | A | 0.00 | 20,000 | 0 | 96,000 | 76 K to 96 K (+26.32 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Grant | A | 0.00 | 9,000 | 0 | 76,000 | 67 K to 76 K (+13.43 %) |
Jan 28 2010 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Option Exercise | A | 2.69 | 6,000 | 16,140 | 6,000 | |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 1.66 | 390,000 | 647,400 | 390,000 | |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Grant | A | 0.00 | 75,000 | 0 | 433,276 | 358.3 K to 433.3 K (+20.93 %) |
Feb 17 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Grant | A | 0.00 | 24,000 | 0 | 356,000 | 332 K to 356 K (+7.23 %) |
Jan 28 2010 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 2.69 | 6,000 | 16,140 | 6,000 | |
Jan 28 2010 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | A | 2.69 | 6,000 | 16,140 | 6,000 | |
Jan 28 2010 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Option Exercise | A | 2.69 | 9,000 | 24,210 | 9,000 | |
Jan 28 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 2.69 | 24,000 | 64,560 | 24,000 | |
Jan 05 2010 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | J | 1.84 | 6,707 | 12,371 | 61,970 | 55.3 K to 62 K (+12.14 %) |
Jan 05 2010 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Buy | J | 1.84 | 1,138 | 2,099 | 333,138 | 332 K to 333.1 K (+0.34 %) |
Dec 24 2009 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Sell | S | 2.15 | 2,000 | 4,300 | 57,710 | 59.7 K to 57.7 K (-3.35 %) |
Aug 26 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.57 | 2,669,000 | 6,859,330 | 10,617,400 | 13.3 M to 10.6 M (-20.09 %) |
Aug 26 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.57 | 770,000 | 1,978,900 | 13,286,400 | 14.1 M to 13.3 M (-5.48 %) |
Aug 26 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.57 | 1,113,550 | 2,861,824 | 14,056,400 | 15.2 M to 14.1 M (-7.34 %) |
Jul 06 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.97 | 84,000 | 249,371 | 15,169,950 | 15.3 M to 15.2 M (-0.55 %) |
Jul 06 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.97 | 24,000 | 71,249 | 15,253,950 | 15.3 M to 15.3 M (-0.16 %) |
Jul 06 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.97 | 34,700 | 103,014 | 15,277,950 | 15.3 M to 15.3 M (-0.23 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.94 | 35,000 | 103,030 | 15,312,650 | 15.3 M to 15.3 M (-0.23 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.94 | 10,000 | 29,437 | 15,347,650 | 15.4 M to 15.3 M (-0.07 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.94 | 13,616 | 40,081 | 15,357,650 | 15.4 M to 15.4 M (-0.09 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.93 | 281,000 | 822,599 | 15,371,266 | 15.7 M to 15.4 M (-1.80 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.93 | 81,000 | 237,119 | 15,652,266 | 15.7 M to 15.7 M (-0.51 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.93 | 117,256 | 343,255 | 15,733,266 | 15.9 M to 15.7 M (-0.74 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.90 | 171,000 | 495,336 | 15,850,522 | 16 M to 15.9 M (-1.07 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.90 | 49,000 | 141,938 | 16,021,522 | 16.1 M to 16 M (-0.30 %) |
Jun 29 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.87 | 71,393 | 204,876 | 16,070,522 | 16.1 M to 16.1 M (-0.44 %) |
Apr 09 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 15,400 | 40,040 | 118,931 | 103.5 K to 118.9 K (+14.87 %) |
Apr 09 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 59,400 | 154,440 | 185,290 | 125.9 K to 185.3 K (+47.18 %) |
Apr 09 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 4.60 | 203,300 | 935,180 | 2,500,928 | 2.7 M to 2.5 M (-7.52 %) |
Apr 09 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 240,000 | 624,000 | 267,600 | 27.6 K to 267.6 K (+869.57 %) |
Apr 09 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 4.60 | 235,500 | 1,083,300 | 1,521,941 | 1.8 M to 1.5 M (-13.40 %) |
Apr 09 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 511,800 | 1,330,680 | 3,369,983 | 2.9 M to 3.4 M (+17.91 %) |
Feb 27 2009 | LGND | LIGAND PHARMACEUTI ... | Dziewanowska Zofia E | VP, Clinical Resear ... | Sell | S | 2.62 | 6,000 | 15,720 | 33,977 | 40 K to 34 K (-15.01 %) |
Feb 19 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 15,400 | 40,040 | 118,931 | 103.5 K to 118.9 K (+14.87 %) |
Feb 19 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 59,400 | 154,440 | 185,290 | 125.9 K to 185.3 K (+47.18 %) |
Feb 19 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 4.60 | 591,100 | 2,719,060 | 2,704,228 | 3.3 M to 2.7 M (-17.94 %) |
Feb 19 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 240,000 | 624,000 | 267,600 | 27.6 K to 267.6 K (+869.57 %) |
Feb 19 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 4.60 | 235,500 | 1,083,300 | 1,521,941 | 1.8 M to 1.5 M (-13.40 %) |
Feb 19 2009 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Buy | P | 2.60 | 511,800 | 1,330,680 | 3,369,983 | 2.9 M to 3.4 M (+17.91 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Option Exercise | A | 2.69 | 100,000 | 269,000 | 100,000 | |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Grant | A | 0.00 | 18,000 | 0 | 59,710 | 41.7 K to 59.7 K (+43.16 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Grant | A | 0.00 | 7,000 | 0 | 41,710 | 34.7 K to 41.7 K (+20.17 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 2.69 | 100,000 | 269,000 | 100,000 | |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 18,000 | 0 | 55,263 | 37.3 K to 55.3 K (+48.31 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 7,000 | 0 | 37,263 | 30.3 K to 37.3 K (+23.13 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | A | 2.69 | 100,000 | 269,000 | 100,000 | |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Grant | A | 0.00 | 18,000 | 0 | 58,000 | 40 K to 58 K (+45.00 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Grant | A | 0.00 | 7,000 | 0 | 40,000 | 33 K to 40 K (+21.21 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | Dziewanowska Zofia E | VP, Clinical Resear ... | Option Exercise | A | 3.50 | 7,000 | 24,500 | 7,000 | |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Option Exercise | A | 2.69 | 106,000 | 285,140 | 106,000 | |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Grant | A | 0.00 | 20,000 | 0 | 67,000 | 47 K to 67 K (+42.55 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Grant | A | 0.00 | 10,500 | 0 | 44,000 | 33.5 K to 44 K (+31.34 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 2.69 | 390,000 | 1,049,100 | 390,000 | |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Grant | A | 0.00 | 75,000 | 0 | 332,000 | 257 K to 332 K (+29.18 %) |
Feb 18 2009 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Grant | A | 0.00 | 28,000 | 0 | 257,000 | 229 K to 257 K (+12.23 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 8.59 | 83,000 | 712,970 | 83,000 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 8.59 | 21,500 | 184,685 | 21,500 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 8.59 | 31,200 | 268,008 | 31,200 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 2,000 | 4,000 | 16,006,215 | 16 M to 16 M (+0.01 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 1,000 | 2,000 | 16,004,215 | 16 M to 16 M (+0.01 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 1,008 | 2,016 | 16,003,215 | 16 M to 16 M (+0.01 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 24,000 | 48,000 | 16,002,207 | 16 M to 16 M (+0.15 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 6,000 | 12,000 | 15,978,207 | 16 M to 16 M (+0.04 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 9,728 | 19,456 | 15,972,207 | 16 M to 16 M (+0.06 %) |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | Kazmi Syed | VP, Bus. Dev. & Str ... | Option Exercise | A | 3.50 | 7,000 | 24,500 | 7,000 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | Sharp John P | VP Finance and CFO | Option Exercise | A | 3.50 | 7,000 | 24,500 | 7,000 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 3.50 | 7,000 | 24,500 | 7,000 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | Dziewanowska Zofia E | VP, Clinical Resear ... | Option Exercise | A | 3.50 | 7,000 | 24,500 | 7,000 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | MEGLASSON MARTIN | V-P, Discovery Rese ... | Option Exercise | A | 3.50 | 10,500 | 36,750 | 10,500 | |
Jan 27 2009 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | President & CEO | Option Exercise | A | 3.50 | 28,000 | 98,000 | 28,000 | |
Dec 24 2008 | LGND | LIGAND PHARMACEUTI ... | PEACOCK BRUCE | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Dec 24 2008 | LGND | LIGAND PHARMACEUTI ... | Burakoff Steven J | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Dec 09 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.98 | 17,000 | 33,699 | 13,537,275 | 13.5 M to 13.5 M (+0.13 %) |
Dec 09 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.98 | 5,000 | 9,912 | 13,520,275 | 13.5 M to 13.5 M (+0.04 %) |
Dec 09 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.98 | 6,283 | 12,455 | 13,515,275 | 13.5 M to 13.5 M (+0.05 %) |
Dec 05 2008 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 57,000 | 116,046 | 13,508,992 | 13.5 M to 13.5 M (+0.42 %) |